Sorrento Therapeutics (LTS:0L85) Moat Score: 0/10 (As of Jul. 09, 2026)


LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics Moat Score?

Sorrento Therapeutics has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Sorrento Therapeutics has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sorrento Therapeutics might have No Moat - No discernible moat.

Sorrento Therapeutics  (LTS:0L85) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sorrento Therapeutics Moat Score Related Terms

LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price